AACR 2022

American Association for Cancer Research

April 8-13, 2022 | New Orleans

Follow Fred Hutch at AACR: #AACR22 |  Facebook  |  Twitter

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world — including Fred Hutchinson Cancer Research Center, whose scientists will be presenting their research at the 2022 meeting.

The theme of the 2022 AACR annual meeting is: Decoding Cancer Complexity | Integrating Science | Transforming Patient Outcomes.  

Friday-Wednesday, April 08-13, 2022
New Orleans, Louisiana
Contact Information:


AACR President-Elect: Phil Greenberg, M.D.

The Rona Jaffe Foundation Endowed Chair Holder

AACR members have elected Greenberg as the AACR president-elect for 2022-2023. He will officially become president-elect on Monday, April 11, 2022, during the AACR’s Business Meeting of Members, and will assume the presidency in April 2023 at the next AACR Annual Meeting in Orlando, Florida.

Read more on Fred Hutch News: Dr. Phil Greenberg becomes president-elect of American Association for Cancer Research

photo of Denise Galloway

Fellow of the AACR Academy: Denise Galloway, Ph.D.

Paul Stephanus Memorial Endowed Chair Holder 

Opening Ceremony 
April 10, 7:45-9:45 a.m.

Galloway will be inducted into the 2022 class of Fellows of the AACR Academy during the annual meeting’s opening ceremony. An expert on the connections between viruses and cancer, Galloway joins 255 scientists who have made significant and enduring impacts in cancer research and serve as a global brain trust of top contributors to cancer science and medicine.

Read more on Fred Hutch News: Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy

Highlights of Fred Hutch Presentations at AACR

Cancer Genetics

Oral presentation: A human paralog genetic interaction map with implications for cancer therapy and tumor evolution
Session: Dharma Master Jiantai Symposium in Targeted Therapy: Novel Genetic Screening Strategies to Identify Therapeutic Targets in Cancer
Presenter: Alice Berger, Ph.D., Innovators Network Endowed Chair holder
Monday, April 11, 10:16 a.m.

Berger will describe a new approach that allows scientists to knock out genes in tandem, which could help identify which gene pairs may play a role in cancer, and which could make for attractive therapeutic targets. Cancer cells exploit gene twins’ overlapping activities, relying on one gene twin to keep key cellular processes going after the first is lost. Researchers studying genes one at a time may miss a gene’s effects on cancer, not suspecting that its twin is pulling the strings in the background. It might lead them to dismiss a key cancer gene (and its therapeutic potential) — a misstep that Berger and her team hope their approach can help scientists avoid.

Related poster: Expanding cancer therapy options by leveraging synthetic lethal interactions between druggable paralogs  
Session: Cancer Genomics 4 
Presenter: Phoebe Parrish 
April 12, 9-12:30 p.m.

Read more on Fred Hutch News: Could gene twins team up against cancer?

Immunotherapy for  Ovarian Cancer

Oral presentation: Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer
Session: Minisymposium in Adoptive Cell Therapy
Presenter: Kristin Anderson, Ph.D.
Tuesday, April 12, 4:05 p.m.

Mesothelin, or MSLN, is a candidate immunotherapy target that contributes to invasive progression and malignancy in ovarian cancer. Anderson, a research associate at Fred Hutch, will describe preclinical experiments which demonstrate that combining engineered MSLN-specific T cells with three antibodies for checkpoint blockade — anti-PD-1, anti-Tim-3 and anti-Lag-3 — results in improved production of tumor-killing cytokines by the T cells and longer survival, compared to the use of the T cells alone or with only one or two antibodies for checkpoint blockade. Because many solid tumors overexpress these immune checkpoints and MSLN, this multi-checkpoint blockade strategy with engineered T cells may have the ability to enhance the efficacy of engineered adoptive T-cell therapy against other cancers.

IDing New Therapies for Advanced Prostate Cancer

Oral presentation: Effective multitargeted kinase inhibitors for metastatic castration-resistant prostate cancer predicted by integrative systems-based modeling
Session: Tyrosine Kinase and Phosphatase Inhibitors
Presenter: Eleonora Dondossola, Ph.D. (MD Anderson Cancer Center)
Tuesday, April 12, 1:30-5:00 p.m.

Using machine learning, deep neural networks and other artificial intelligence tools, Fred Hutch researchers in the labs of Drs. Taranjit Gujral and Peter Nelson and their collaborators identified inhibitors that block several kinases involved in prostate cancer growth and progression but aren’t likely to cause widespread side effects. The researchers’ preclinical testing suggests that combining multi-targeted kinase inhibitors with chemotherapy may represent an effective strategy for treating people with this cancer.

Read more on Fred Hutch News: Using AI to identify potential COVID-19, cancer therapies

More Fred Hutch Presentations


Online-only poster: Cook and Move for Your Life: A pilot study of an online intervention to improve diet and physical activity among breast cancersurvivors 
Session: Phase I Clinical Trials 
Presenter: Heather Greenlee, N.D., Ph.D., MPH
April 8, 12-1 p.m.

Online-only poster: User characteristics of “Cook For Your Life” - a website designed to support cancer patients and survivors 
Session: Population Sciences 
Presenter: Heather Greenlee, N.D., Ph.D., MPH 
April 8, 12-1 p.m.

Online-only poster: Predictors of objectively-measured sedentary time during the COVID-19 pandemic among breast cancer survivors participating in a diet and physical activity intervention 
Session: Population Sciences 
Presenter: Heather Greenlee, N.D., Ph.D., MPH 
April 8, 12-1 p.m.

Online-only poster: Cardiovascular disease risk associated with breast cancer chemotherapy drugs: The Pathways Heart Study 
Session: Drug Discovery 
Presenter: Hanjie Shen, M.S.
April 8, 12-1 p.m.

Poster: Outcomes of an expanded access program for patients with gastrointestinal stromal tumors in low- and middle-income countries
Session: Clinical Research in Special Populations / Supportive Care and Survivorship Research 
Presenter: Edward Briercheck , M.D., Ph.D.
April 10, 1:30-5 p.m.

Prevention and Screening 

Online-only poster: The ABID (Assessing the gut microbiota and Individual Diet) Study in the Navajo Nation 
Sesson: Population Sciences 
Presenter: Dornell Pete 
April 8, 12-1 p.m.

Poster: Will novel systemic treatments alter the benefit of lung cancer screening?: A microsimulation study 
Session: Descriptive Epidemiology Covering Cancer Incidence, Mortality, Clusters, and Trends 
Presenter: Kemal Caglar Gogebakan, Ph.D.
April 10, 1:30-5 p.m.

Cancer Immunology 

Oral educational presentation: The function of immune cells in residual disease and cancer recurrence 
Session: Cancer Dormancy and Immune Regulation 
Presenter: James Alvarez, Ph.D.
April 8, 3:30-3:50 p.m.

Poster: CD8 T cells display distinct trajectories of T cell exhaustion in the bone marrow of mice with multiple myeloma 
Session: Molecular Signaling and Metabolic and Epigenetic Regulation in Adaptive Tumor Immunity 
Presenter: Simone Minnie, Ph.D.
April 11, 9-12:30 p.m.

Poster: Cellular profiling of leukapheresis and infusion products of patients enrolled in CD19 CAR T cell therapy identifies biomarkers associated with clinical outcomes 
Session: Proteomics, Signaling Networks, and Biomarker Discovery 
Presenter: Tony Chour 
April 13, 9 a.m.-12:30 p.m.

Late-breaking poster: Duplex Sequencing reveals ubiquitous clonal hematopoiesis and complex donor-recipient clonal dynamics following HSCT 
Session: Late-Breaking Research: Tumor Biology 2 
Presenter: Jake Higgins, Ph.D.
April 11, 9-12:30 p.m.

Biomarkers and Therapeutic Targets

Poster: Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001 - folate receptor alpha-directed C’Dot-drug-conjugate 
Session: Drug Conjugates / Bispecific Antibodies 
Presenter: Soheil Meshinchi, M.D. 
April 11, 9-12:30 p.m.

Poster: UBTF tandem duplications (UBTF-TD) in childhood AML: Enrichment in FLT3-ITD and association with clinical outcome 
Session: Translational Research: Molecular and Clinical 
Presenter: Leila Robinson 
April 12, 1:30-5 p.m.

Poster: Identification of USP9X as a novel regulator of RIT1 protein abundance and as a potential therapeutic target in RIT1-driven lung cancer 
Session: GTPase and Ubiquitin Signaling 
Presenter: Amanda Riley 
April 12, 1:30-5 p.m.

Latest AACR News

All news
Dr. Phil Greenberg becomes president-elect of American Association for Cancer Research Immunologist looks ahead to international leadership role April 12, 2022
Could gene twins team up against cancer? New approach uncovers gene duplications that could be targets for cancer drugs August 31, 2021
Using AI to identify potential COVID-19, cancer therapies Early findings show current drugs might be repurposed to calm COVID-19’s cytokine storms, treat metastatic prostate cancer September 30, 2021
Dr. Denise Galloway elected Fellow of the American Association for Cancer Research Academy Cancer biologist contributed basic and translational insights that made the cancer-preventive HPV vaccine possible March 22, 2022

Contact Our Media Relations Team

For more information or to arrange an interview, please email or call our media relations team.